AI, Neuroscience, and Pharma's $500 Billion Problem: A Candid Talk with BMS’s Chief Medical Officer on the Future of Drug Development to Agentic Medical Science Liaisons
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
AI, Neuroscience, and Pharma's $500 Billion Problem: A Candid Talk with BMS’s Chief Medical Officer on the Future of Drug Development to Agentic Medical Science Liaisons
-
Narrated by:
-
By:
In this episode of The Will Soliman Podcast, William Soliman sits down with Dr. Cristian Massacesi, high-energy Chief Medical Officer & Head of Drug Development at Bristol Myers Squibb (BMS). They explore how AI is reshaping drug discovery and clinical development, from target validation to trial execution.
Topics include:
How AI is already accelerating drug discovery and clinical trials
Why neuroscience and neurodegenerative diseases have been so challenging—and why there’s new hope
The coming $500B patent cliff and what it means for Big Pharma and investors
The future of synthetic control arms, digital twins, and real-world evidence
How AI can augment medical affairs and MSLs, not replace them
Big changes in healthcare innovation
Perfect for listeners in pharma, biotech, healthcare investing, clinical research & development, and medical affairs who want an inside view of where drug development is headed next.
To Find Will Soliman on LinkedIn
Related Sites:
- Accreditation Council for Medical Affairs
- Medical Science Liaisons
- Prior Authorization and Field Reimbursement
- White Manna Capital Partners
Have a Topic or Guest Suggestion: Contact Us